Bacterial Pneumonia

Infectious Diseases
2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

On Market (1)

Approved therapies currently available

Paratek Pharmaceuticals
NUZYRAApproved
omadacycline
Paratek Pharmaceuticals
Tetracycline-class Antibacterial [EPC]intravenous2018

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Paratek Pharmaceuticals
1 program
1
1
OmadacyclinePhase 3Small Molecule1 trial
Active Trials
NCT02531438Completed774Est. Mar 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Paratek PharmaceuticalsOmadacycline

Clinical Trials (1)

Total enrollment: 774 patients across 1 trials

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Start: Nov 2015Est. completion: Mar 2017774 patients
Phase 3Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space